I read with interest your story "Government To Industry: Join War On Drugs" [The Scientist, Nov. 26, 1990, page 1]. For the last three years, our company, NDA International Inc., has focused upon the development of an anti-addiction agent, Ibogaine, as an interrupter of heroin and cocaine dependency.

NDA International has funded research projects in the United States, Canada, and the Netherlands. These have all supported our claims for ENDABUSE (Ibogaine HCl). Research performed at Erasmus University, Rotterdam, provided data that ENDABUSE reduced certain behavioral characteristics in naloxone-precipitated morphine withdrawal. Investigators at Albany Medical College have shown reversal and blockade of morphine-induced dopamine increases in the nucleus accumbens and striatum as well as decreases in self-administration of morphine by Ibogaine-treated rats.

Preclinical studies at the Medical College of Virginia, Richmond, and the University of Michigan Medical School, Ann Arbor, demonstrated that Ibogaine was neither an opiate nor an antagonist, does...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?